Transcriptomic analysis from the melanoma patients reveals that responsiveness to the pretreatment with anti-CTLA-4 showed a positive correlation with increased tumor mutational burden (TMB) and increased expression of neoantigen and cytolytic markers in the immune microenvironment [169]. This evidence concerns the gene CTLA4 and melanoma.